Extrapyramidal Treatment Market Size, Share & Growth [2032]

Report Description

Market Outlook:

The global extrapyramidal treatment market was estimated at USD 1,209.0 Million in 2023 and is anticipated to reach USD 1,703.7 Million by 2032, expanding at a CAGR of 3.9% during the forecast period.

Extrapyramidal symptoms (EPS) are a group of movement disorders that result from dysfunction in the extrapyramidal system, a neural network in the brain responsible for controlling voluntary movements. These symptoms arise as side effects of certain medications, particularly antipsychotic drugs, or as manifestations of underlying neurological conditions. EPS refers to the management and care provided to individuals with movement disorders that involve the extrapyramidal system, a neural network in the brain responsible for controlling voluntary movements. These movement disorders include conditions such as parkinson's disease, dystonia, tremors, and chorea. The pharmaceutical industry is focused on developing antipsychotic drugs that have a lower risk of EPS.

Get Free Sample Report

COVID-19 Impact on the Global Extrapyramidal Treatment Market

The research report finds that the COVID-19 pandemic has had various effects on the global extrapyramidal treatment market, which primarily deals with medications and therapies for conditions affecting the extrapyramidal system, such as parkinson's disease, dystonia, and other movement disorders. The clinical trials investigating new therapies for movement disorders may have been delayed or interrupted due to COVID-19-related restrictions. This postpones the introduction of novel treatments to the market and impact the pipeline of potential extrapyramidal treatments in development.

Artificial Intelligence (AI) Impact on the Global Extrapyramidal Treatment Market

AI-powered drug discovery platforms accelerate the identification and optimization of novel therapeutic compounds for extrapyramidal disorders. By analyzing chemical structures, pharmacological properties, and biological activity data, AI algorithms predict the likelihood of a candidate molecule to modulate specific targets implicated in movement disorders. This accelerates the drug discovery process and expand the pipeline of potential treatments. Artificial Intelligence (AI) in Drug Discovery, to evaluate huge amounts of data to find new therapeutic targets and accelerate the drug development process. AI technologies enable the identification of molecular targets and pathways underlying extrapyramidal disorders, paving the way for the development of targeted therapies. By analyzing genetic, proteomic, and transcriptomic data, AI identify potential drug targets and biomarkers for patient stratification, facilitating the development of precision medicine approaches in the treatment of movement disorders.

Macro-economic Factors

Healthcare Expenditure

Higher healthcare expenditure often correlates with better access to healthcare services, including specialized treatment for movement disorders. Healthcare expenditure contributes to funding for research and development initiatives aimed at discovering new treatments and improving existing therapies for movement disorders. Pharmaceutical companies and research institutions rely on healthcare funding to conduct clinical trials, develop innovative drugs, and advance medical technology in this field. Healthcare expenditure supports the development and maintenance of healthcare infrastructure, including hospitals, clinics, and rehabilitation centers equipped to diagnose and treat movement disorders. Adequate healthcare infrastructure is essential for providing timely and effective care to patients with extrapyramidal disorders.

According to American Medical Association, in 2022, health-care spending in the United States rose by 4.1% to $4.4 trillion, or $13,493 per person. This growth rate is comparable to the pre-pandemic rate (4.1% in 2019). Although government spending to manage the pandemic led to significant increases in NHE, these expenditures fell significantly in 2021, while medical goods and services usage rebounded. By 2022, top-level health spending patterns will be more similar to those observed prior to the pandemic.

Market Dynamics

Major Driver- Increasing Prevalence of Movement Disorders

The rising prevalence of movement disorders, particularly among aging populations, is a significant driver of the extrapyramidal treatment market. Factors such as demographic aging, lifestyle changes, and improved diagnosis contribute to the growing patient population in need of treatment for conditions like Parkinson's disease. For instance, according to WHO 8.5 million individuals having Parkinson disease (PD) in 2019. The prevalence of PD has doubled in the past 25 years.

Existing Restraint- Adverse Effects and Safety Concerns

Adverse effects such as motor fluctuations, dyskinesias, cognitive impairments, and psychiatric symptoms affects patient tolerability and adherence to treatment regimens. Patients may discontinue or modify their medications due to intolerable side effects, leading to suboptimal treatment outcomes and disease progression. Concerns about adverse effects may influence physician prescribing patterns and treatment decisions. Healthcare providers may be cautious when prescribing medications with known safety risks, particularly in elderly or medically complex patients, leading to underutilization of potentially effective therapies.

Emerging Opportunity- Targeted Therapies and Precision Medicine

Targeted therapies and precision medicine enable healthcare providers to tailor treatment strategies to the specific molecular and genetic characteristics of individual patients. By identifying biomarkers, genetic variants, and disease subtypes associated with extrapyramidal disorders, precision medicine offers opportunities to optimize treatment efficacy, minimize adverse effects, and improve patient outcomes. Precision medicine approaches facilitate the development of neuroprotective and disease-modifying treatments that slow or halt the progression of extrapyramidal disorders. Therapeutic strategies targeting alpha-synuclein aggregation, mitochondrial dysfunction, neuroinflammation, and oxidative stress offer opportunities to intervene in disease pathogenesis and preserve neuronal function.

Scope of the Report

The report on the global extrapyramidal treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Segmental Outlook

Based on symptoms type, the global extrapyramidal treatment market is segmented into pseudo-parkinsonism, dystonia symptom, akathisia (restlessness), tardive dyskinesia. The Pseudo-parkinsonism segment is anticipated to hold XX% market share in 2023, due to increasing prevalence and use of antipsychotic medications in various clinical settings, including psychiatry, neurology, and primary care. As a result, there is an increased demand for treatment options to manage the motor symptoms associated with pseudo-parkinsonism.

On the basis of drug type, the global extrapyramidal treatment market is classified as atypical antipsychotics (aripiprazole, clozapine, quetiapine and others), anticholinergic drug (benztropine, trihexyphenidyl, others), atypical antidepressant, antihistamine, benzodiazepine drugs (lorazepam, clonazepam, others), others. The anticholinergic drug segment is anticipated to hold 32.4% share of the market in 2023, due to increasing anticholinergic drug to manage neuropsychiatric symptoms commonly associated with neurological conditions such as Parkinson's disease, Huntington's disease, and multiple system atrophy. These medications help to regain the balance of chemical messengers in the brain that are disrupted by antipsychotic medications. Examples of anticholinergics include benztropine (Cogentin) and trihexyphenidyl (Artane).

Get Free Sample Report

In terms of end-user, the extrapyramidal treatment market is categorized as hospitals, clinics, research & academic center. The hospitals segment is expected to hold a market share of 45.5% in 2023, as hospitals, particularly those with specialized neurology departments or movement disorder centers, play a key role in the diagnosis and management of extrapyramidal disorders. These facilities offer access to neurologists, movement disorder specialists, neurosurgeons, rehabilitation therapists, and other healthcare professionals with expertise in treating movement disorders.

Get Free Sample Report

In terms of sales channel, the extrapyramidal treatment market is categorized as online pharmacy, offline pharmacy (hospital pharmacy, retail pharmacy). The online pharmacy segment is expected to hold a market share of XX% in 2023, as online pharmacies provide individuals with convenient access to a wide range of extrapyramidal medications, including antipsychotics, antidepressants, anticholinergics, and other pharmacological agents used in the management of movement disorders. Patients order prescriptions online and have medications delivered directly to their doorstep, eliminating the need for in-person visits to traditional brick-and-mortar pharmacies.

Regional Outlook

On the basis of region, the global extrapyramidal treatment market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa (MEA).

The market in North America is projected to expand at a CAGR of 7.2% during the forecast period, primarily due to high disease burden in North America, particularly the United States and Canada, has a substantial burden of extrapyramidal disorders such as Parkinson's disease, essential tremor, dystonia, and Huntington's disease.

Europe held XX% share of the market in 2023, and the market in the region is expected to expand at a CAGR of XX% during the forecast period, as Europe is a hub of research and innovation in the field of extrapyramidal treatment, with numerous academic institutions, research centers, and pharmaceutical companies conducting clinical trials, translational research, and technology development initiatives. Collaborative research networks and funding programs support advancements in treatment options and personalized medicine approaches.

Get Free Sample Report

Key Benefits for Industry Participants & Stakeholders

• In-depth Analysis of the Global Extrapyramidal Treatment Market

• Historical, Current, and Projected Market Size in terms of Value

• Potential & Niche Segments and Regions Exhibiting Promising Growth Covered

• Industry Drivers, Restraints, and Opportunities Covered in the Study

• Recent Industry Trends and Developments

• Competitive Landscape & Strategies of Key Players

• Neutral Perspective on Global Extrapyramidal Treatment Market performance